Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late December 2019 in Wuhan, China. The virus has since spread across the globe, evolving into the COVID-19 pandemic, crippling ...
BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...
Severe adverse reactions were reported after the AstraZeneca ChAdOx1-S-nCoV-19 vaccine (ChAd). This prompted the European health authorities to recommend the preferred second dose to be Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results